Cargando…
Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease
Background and Objectives: To evaluate the clinical efficacy of periocular botulinum toxin A (BTA) injection in patients with intractable dry eye disease (DED). Materials and Methods: Medical records of patients with intractable DED who underwent periocular BTA injection from December 2019 to March...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998232/ https://www.ncbi.nlm.nih.gov/pubmed/33800125 http://dx.doi.org/10.3390/medicina57030247 |
_version_ | 1783670504496824320 |
---|---|
author | Choi, Eun Woo Yeom, Dong Ju Jang, Sun Young |
author_facet | Choi, Eun Woo Yeom, Dong Ju Jang, Sun Young |
author_sort | Choi, Eun Woo |
collection | PubMed |
description | Background and Objectives: To evaluate the clinical efficacy of periocular botulinum toxin A (BTA) injection in patients with intractable dry eye disease (DED). Materials and Methods: Medical records of patients with intractable DED who underwent periocular BTA injection from December 2019 to March 2020 were reviewed retrospectively. Patients were injected with 2.5 units of BTA in the medial part of the lower eyelids. The clinical data collected included age, sex, ocular surface disease index (OSDI) score, tear film break up time (TBUT), Schirmer test results, tear osmolarity (I-PEN), and tear meniscus height (TMH) measured by anterior segment optical coherence tomography. All subjective and objective data were collected before treatment and at 1 month after treatment. Results: Twenty-eight consecutive patients were eligible for chart review and analysis. Significant improvements in OSDI, tear osmolarity, and TMH were observed at 1 month after periorbital BTA injection. At the baseline and 1-month follow-up examinations, OSDI scores were 62.22 ± 21.30 and 47.98 ± 17.23, respectively (p < 0.001). TMH increased significantly after treatment (82.25 ± 40.50 at baseline vs. 138.02 ± 66.62 1-month after treatment; p < 0.001). Tear osmolarity using I-PEN showed a significant decrease after treatment (320.82 ± 24.66 at baseline vs. 302.75 ± 22.33 at 1 month after treatment; p < 0.001). No significant differences were found in TBUT or Schirmer test results before and after BTA injection. Conclusions: BTA injection into the medial part of the eyelid improves dry eye symptoms, the amount of tear retention, and tear osmolarity. Based on the objective parameters of the tear condition, this study supports the idea of BTA use as a potential treatment option for patients with intractable DED. |
format | Online Article Text |
id | pubmed-7998232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79982322021-03-28 Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease Choi, Eun Woo Yeom, Dong Ju Jang, Sun Young Medicina (Kaunas) Article Background and Objectives: To evaluate the clinical efficacy of periocular botulinum toxin A (BTA) injection in patients with intractable dry eye disease (DED). Materials and Methods: Medical records of patients with intractable DED who underwent periocular BTA injection from December 2019 to March 2020 were reviewed retrospectively. Patients were injected with 2.5 units of BTA in the medial part of the lower eyelids. The clinical data collected included age, sex, ocular surface disease index (OSDI) score, tear film break up time (TBUT), Schirmer test results, tear osmolarity (I-PEN), and tear meniscus height (TMH) measured by anterior segment optical coherence tomography. All subjective and objective data were collected before treatment and at 1 month after treatment. Results: Twenty-eight consecutive patients were eligible for chart review and analysis. Significant improvements in OSDI, tear osmolarity, and TMH were observed at 1 month after periorbital BTA injection. At the baseline and 1-month follow-up examinations, OSDI scores were 62.22 ± 21.30 and 47.98 ± 17.23, respectively (p < 0.001). TMH increased significantly after treatment (82.25 ± 40.50 at baseline vs. 138.02 ± 66.62 1-month after treatment; p < 0.001). Tear osmolarity using I-PEN showed a significant decrease after treatment (320.82 ± 24.66 at baseline vs. 302.75 ± 22.33 at 1 month after treatment; p < 0.001). No significant differences were found in TBUT or Schirmer test results before and after BTA injection. Conclusions: BTA injection into the medial part of the eyelid improves dry eye symptoms, the amount of tear retention, and tear osmolarity. Based on the objective parameters of the tear condition, this study supports the idea of BTA use as a potential treatment option for patients with intractable DED. MDPI 2021-03-08 /pmc/articles/PMC7998232/ /pubmed/33800125 http://dx.doi.org/10.3390/medicina57030247 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Choi, Eun Woo Yeom, Dong Ju Jang, Sun Young Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title | Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title_full | Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title_fullStr | Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title_full_unstemmed | Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title_short | Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease |
title_sort | botulinum toxin a injection for the treatment of intractable dry eye disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998232/ https://www.ncbi.nlm.nih.gov/pubmed/33800125 http://dx.doi.org/10.3390/medicina57030247 |
work_keys_str_mv | AT choieunwoo botulinumtoxinainjectionforthetreatmentofintractabledryeyedisease AT yeomdongju botulinumtoxinainjectionforthetreatmentofintractabledryeyedisease AT jangsunyoung botulinumtoxinainjectionforthetreatmentofintractabledryeyedisease |